Scarica l'app Stockscreener
69.76
0.81%
0.5186
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$69.24
Aprire:
$69.35
Volume 24 ore:
3.31M
Relative Volume:
0.56
Capitalizzazione di mercato:
$27.21B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
48.83
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
+3.56%
1M Prestazione:
+5.17%
6M Prestazione:
-17.03%
1 anno Prestazione:
-17.73%
Intervallo 1D:
$69.02
$70.38
Intervallo di 1 settimana:
$65.92
$72.50
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
69.76 | 27.00B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
122.03 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
365.35 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.38 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
97.32 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.29 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Stock Declines Following Strong Preliminary Q4 Results - TradingView — Track All Markets
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - TradingView — Track All Markets
MGO One Seven LLC Buys 14,699 Shares of DexCom, Inc. $DXCM - MarketBeat
How Do Investors Really Feel About DexCom Inc? - Benzinga
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Dexcom CEO Talks G8 CGM Sensor - Medical Device and Diagnostic industry
DexCom's Q4 2025 Earnings: What to Expect - inkl
Dexcom’s new CEO talks affordability, over-the-counter glucose sensors - Healthcare Brew
DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 - Insider Monkey
New Dexcom CEO Jake Leach talks 2026 roadmap, next-gen tech - MassDevice
Dexcom’s Jake Leach on the future of continuous glucose monitoring - Modern Healthcare News
Is DexCom (DXCM) Pricing Justified After Recent Multi Year Share Price Weakness - Yahoo Finance
RWC Asset Management LLP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Bought by PKO Investment Management Joint Stock Co - MarketBeat
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Sells 17,554 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance By Investing.com - Investing.com Nigeria
Barclays Downgrades DexCom (DXCM), Lowers Price Target to $71.00 - GuruFocus
Why This Medical Device Company Is the Top Stock in the S&P 500 Today - Barron's
Dexcom reports 13% rise in preliminary Q4 revenue, issues 2026 outlook - MSN
Why DexCom Is the Top Stock in the S&P 500 Today - Barron's
Barclays Downgrades DexCom to Underweight From Equal Weight, Adjusts Price Target to $71 From $80 - marketscreener.com
DexCom (DXCM) Reports Strong Preliminary Q4 and FY 2025 Revenue Growth - GuruFocus
Dexcom Updates Fiscal 2025 Revenue Guidance; Sets 2026 Outlook - marketscreener.com
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance - Investing.com
(DXCM) DexCom Expects 2026 Total Revenue Range $5.16B$5.25B, vs. FactSet Est of $5.23B - marketscreener.com
Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch - TradingView — Track All Markets
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
DexCom, Inc. (DXCM) Investor Outlook: 26.63% Potential Upside And Strong Buy Ratings - DirectorsTalk Interviews
Assessing DexCom (DXCM) Valuation As Analyst Actions And Conference Spotlight Shape Sentiment - simplywall.st
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Mizuho Adjusts Price Target on DexCom to $78 From $75, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $86 From $84, Maintains Outperform Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Lowers Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Why Dexcom (DXCM) Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform - Sahm
How DexCom Inc. stock compares to growth peersMarket Movement Recap & Low Risk High Reward Ideas - Улправда
Will DexCom Inc. stock benefit from sector rotationTrade Entry Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
DexCom (DXCM) Stock Falls as Analysts Adjust Price Targets | Jan 2026News and Statistics - IndexBox
How DexCom Inc. stock performs in weak economyTake Profit & Safe Capital Growth Stock Tips - ulpravda.ru
Dexcom Finishes Off Class Claims Over Sales Growth Statements - Bloomberg Law News
DexCom (DXCM) Stock Trades Down, Here Is Why - Finviz
Why DexCom Inc. stock is rated strong buyTreasury Yields & Reliable Volume Spike Trade Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:15 - Улправда
Is DexCom Inc. stock a good choice for value investorsVolume Spike & Short-Term Trading Opportunity Alerts - ulpravda.ru
Moran Wealth Management LLC Grows Stake in DexCom, Inc. $DXCM - MarketBeat
Dexcom CEO Jake Leach begins tenure with focus on metabolic health - Investing.com Nigeria
Dexcom CEO Jake Leach Takes the Helm, Presents Future at CES - Medical Product Outsourcing
Dexcom enters next era of continued innovation with Jake Leach as chief executive officer - marketscreener.com
Dexcom CEO Jake Leach begins tenure with focus on metabolic health By Investing.com - Investing.com South Africa
Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer - DexCom Investor Relations
Is DexCom, Inc.'s (NASDAQ:DXCM) Recent Stock Performance Tethered To Its Strong Fundamentals? - 富途牛牛
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):